NICE Conference 2023 presentations
NICE evolution: learning systems
NICE impact: focusing on what matters most
NICE advice: useful and useable
Real-world data (RWD)
Does RWD deliver results which are significantly different from clinical trials, and what are the implications of RWD for future drug development? NICE is now using RWD-informed rolling appraisals to provide technology assessments which keep pace with changing COVID variants, but there is a lot more NICE could do. How could the COVID approach be scaled up to strengthen the speed and impact of NICE’s work?
With services being overwhelmed, particularly for children and young people, how can NICE support services to meet demand, through timely guidance and evaluating mental health apps? What is the role of patient reported outcomes in judging apps’ effectiveness? In the face of such an immense overload, what level of performance is required from digital technology to make it useful? Examples will include services for depression and self-harm.
Digital living guidelines
Is there a trade-off between quality and speed? Healthcare teams need guidelines which tackle the issues that matter, are delivered quickly, are easily accessible and easy to implement. NICE’s ambition is to update recommendations on key topics within 3 to 6 months of practice-changing evidence emerging. This session will explore how we are piloting this new approach, discuss how to manage any trade-off between speed and quality and invite ideas about how we could improve our guidelines.
How do we ensure the UK is an attractive place for the life sciences industry to do business and the UK is delivering the solutions the NHS needs? How does the UK balance its robust approach to pricing with R&D support, such as working with the NHS on clinical trials and the collection of real-world data?
*No presentation available
New models of care - a focus on virtual wards
New ways of working such as virtual wards and patient-initiated follow-ups could deliver big improvements in productivity and patients’ quality of life. But the evidence supporting innovations in care delivery is often poor and implementation is hard in a system under pressure. We will discuss the evidence on virtual wards from our deep dive over recent months, look at how we can improve evidence around other potential game-changers, and debate how to make implementation manageable and successful.
Making place-based integrated care a reality
How does NICE help the health and care system build place-based care around people rather than institutions? How does integrated care manage population health and reduce health inequalities?
Liberating data – in conversation with Professor Ben Goldacre
Improving connections between the vast datasets across healthcare, industry and research could deliver major benefits in patient outcomes, health service management and economic growth, while the pandemic showed the potential for gathering, analysing and acting on data in almost real-time. What needs to change to deliver on this extraordinary potential? Richard Vize leads a conversation with Prof Ben Goldacre, director of the Bennett Institute for Applied Data Science, University of Oxford, with plenty of audience engagement.
How can NICE best support the health and care system users to implement its guidance, improve health outcomes and make the best use of resources? This will be an opportunity for the audience to tell NICE about what more they need from us to do their jobs.
*No presentation available
Innovation in action
Case studies highlighted by NICE, presented by the health and care staff who delivered them, to show how implementing guidance leads to innovations in care which benefit patients.
With many more medicines coming through for evaluation, NICE is piloting new approaches to ensure decisions are timely, appraisals are proportionate, and that NICE has the capability to evaluate increasing complex medicines that may be disruptive to current methods. How should NICE further develop its approaches to guidance development? How are changes to NICE’s evaluation of treatments for the most severe conditions benefitting patients? What’s on the horizon for future modular updates to NICE’s methods of evaluation? What role can the HTA Lab play in developing NICE’s future methods?
Healthcare and net zero
The NHS has a roadmap to be net zero by 2040. How does the health service account for environmental impact in its management and care? What trade-offs are tolerable between financial and environmental costs? Can a course of care ever be denied on environmental grounds? Should net zero drive NICE’s topic choices? Could NICE guidelines deliver better patient and environmental outcomes, such as by focusing on prevention? How does NICE start to thread net zero through healthcare guidance so that it becomes everyone’s responsibility?
How do we address health inequalities in NICE guidance? How do we ensure the voices of patients and the public shape our guidelines, rather than just have a chance to comment on them. How do we involve stakeholders in shaping implementation and measuring impact to ensure guidance narrows rather than exacerbates inequalities?